15 completed, 6 unknown, 5 recruiting, 2 terminated. 7 Phase 4, 6 Phase 3, 5 Phase 2, 4 Phase 1, 2 Not applicable.
Follow CT-P13: new trials by email Literature Review of CT-P13 trials Research Report on CT-P13
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Medical Treatment Versus Surgery in Stricturing Small Bowel Crohn's Disease Azathioprine + infliximab, Intestinal resection - Crohn Disease | Not applicable | Not yet recruiting | Nantes University Hospital | 150 | 2026-10-01 | 2026-06-23 |
| Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Cytokine Release Syndrome, Recurrent Multiple Myeloma | Phase 2 | Recruiting | Naresh Bumma | 35 | 2026-07-17 | 2026-10-06 |
| Pharmacokinetics, Efficacy and Safety of CT-P13 Subcutaneous as Induction Therapy in Patients With Active CD or UC CT-P13 - Inflammatory Bowel Diseases | Phase 3 | Unknown | CMC Ambroise Paré | 130 | 2024-07-10 | 2024-07-31 |
| Efficacy and Safety of Infliximab Biosimilar in Treatment of Moderate to Severe Psoriasis; A Single-arm Clinical Trial Infliximab-dyyb Biosimilar (Remsima) - Moderate to Severe Chronic Plaque Psoriasis | Phase 1 / Phase 2 | Unknown | Services Institute of Medical Sciences, Pakistan | 104 | 2023-11-06 | 2024-09-19 |
| TDM-based Infliximab Treatment for Active Perianal Fistulizing Crohn's Disease TDM-based infliximab intravenous therapy, Standard infliximab intravenous therapy - Crohn Disease, Infliximab | Phase 4 | Recruiting | Asan Medical Center | 86 | 2023-11-01 | 2024-05-14 |
| Efficacy and Safety of Infliximab Biosimilar in the Treatment of Resistant Hidradenitis Suppurativa Infliximab-dyyb biosimilar - Hidradenitis Suppurativa | Early Phase 1 | Completed | Services Institute of Medical Sciences, Pakistan | 37 | 2022-10-01 | 2023-11-29 |
| EFFICACY AND SAFETY OF S.C. INFLIXIMAB IN PATIENTS SWITCHED FROM I.V. FORMULATION OF INFLIXIMAB CT-P13 - Inflammatory Bowel Diseases, Rheumatologic Disease | Unknown | IRCCS San Raffaele | 250 | 2022-09-14 | 2023-02-09 | |
| Efficacy and Safety of Infliximab Biosimilar Remsima in Psoriasis Remsima - Psoriasis | Phase 4 | Completed | Ghurki Trust and Teaching Hospital | 51 | 2022-03-10 | 2023-09-21 |
| REduCed Dose of TNFi in Patients With Ankylosing SpondyliTis (RECAST) Adalimumab and its biosimilars, Biological: Etanercept and its biosimilars, Golimumab - Ankylosing Spondylitis, Axial Spondyloarthritis | Phase 4 | Unknown | Hanyang University Seoul Hospital | 448 | 2022-01-15 | 2021-12-20 |
| Management of Moderate POstoperative Recurrence in Crohn's Disease: a randoMizEd contROLled Trial of Therapeutic Escalation, the POMEROL Trial. (POMEROL) Infliximab CT-P13, Immunosuppressors (Thiopurines or Methotrexate) - Crohn Disease | Phase 4 | Completed | Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives | 213 | 2021-12-21 | 2026-11-06 |
| InDuctIon TREatment with SubCuTaneous Infliximab for Crohn's Disease Infliximab subcutaneous, Immunosuppressive Agents - Inflammatory Disease, Disease Crohn | Phase 3 | Recruiting | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 158 | 2021-11-25 | 2024-12-10 |
| De-escalation of Anti-TNF Therapy in Inflammatory Bowel Disease Infliximab, Adalimumab - Inflammatory Bowel Diseases, Crohn Disease | Phase 4 | Enrolling by invitation | University Medical Center Groningen | 148 | 2021-03-11 | 2025-01-06 |
| Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer Best Practice, Biospecimen Collection, Endoscopic Procedure - Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8 | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 800 | 2021-02-21 | 2026-07-15 |
| MIS-C Comparative Effectiveness Study Infliximab, Anakinra, Methylprednisolone - Multisystem Inflammatory Syndrome-Children | Phase 2 / Phase 3 | Completed | University of California, San Diego | 73 | 2020-12-22 | 2025-11-04 |
| Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma Infliximab, Vedolizumab - Colitis, Lung Non-Small Cell Carcinoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 47 | 2020-07-09 | 2026-07-15 |
| TITRATE (inducTIon for acuTe ulceRATivE Colitis) Infliximab - Colitis, Ulcerative | Phase 4 | Terminated | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 50 | 2019-09-04 | 2025-02-06 |
| Post-Operative Crohn's Disease Outcome in Children Azathioprine, Anti-TNF Drug - Crohn Disease | Recruiting | Schneider Children's Medical Center, Israel | 100 | 2019-02-11 | 2025-05-15 | |
| To Compare the Efficacy, Pharmacokinetics and Safety Between CT-P13 and China Approved Remicade When Co-administered With Methotrexate in Patients With Active Rheumatoid Arthritis CT-P13, Remicade - Rheumatoid Arthritis | Phase 3 | Completed | Celltrion | 270 | 2018-11-12 | 2021-09-14 |
| Safety and Effectiveness Study of Remsima® in the Treatment of Inflammatory Bowel Diseases Among Saudi Arabia Patients Infliximab - Inflammatory Bowel Diseases, Crohn Disease | Completed | Hikma Pharmaceuticals LLC | 157 | 2018-08-26 | 2021-02-23 | |
| Anti-tumor Necrosis Factor in Patients With Ulcerative Colitis in Clinical Remission: to Continue or Not? Discontinuation of anti-TNF treatment, Continuation of anti-TNF treatment - Colitis,Ulcerative | Not applicable | Completed | Helse Møre og Romsdal HF | 174 | 2017-06-09 | 2025-05-31 |
Showing 20 of 31. Sign in to see all of them.
Crohn Disease (13) · Colitis, Ulcerative (8) · Arthritis, Rheumatoid (7) · Inflammatory Bowel Diseases (5) · Arthritis, Psoriatic (2) · Carcinoma, Non-Small-Cell Lung (2) · Colitis (2) · Spondylitis, Ankylosing (2) · Urogenital Neoplasms (2) · Autoimmune Diseases (1) · Axial Spondyloarthritis (1) · Collagen Diseases (1) · Constriction, Pathologic (1) · Cytokine Release Syndrome (1) · Hidradenitis Suppurativa (1)
Celltrion (4) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (2) · Hikma Pharmaceuticals LLC (2) · M.D. Anderson Cancer Center (2) · Pfizer (2) · Services Institute of Medical Sciences, Pakistan (2) · Asan Medical Center (1) · CMC Ambroise Paré (1) · Ced Service GmbH (1) · Diakonhjemmet Hospital (1) · Ghurki Trust and Teaching Hospital (1) · Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives (1) · Hanyang University Seoul Hospital (1) · Helse Møre og Romsdal HF (1) · IRCCS San Raffaele (1)
France (5) · Netherlands (5) · United States (5) · South Korea (4) · Czechia (3) · Germany (3) · Norway (3) · Pakistan (3) · Spain (3) · Belgium (2) · Greece (2) · Israel (2) · Italy (2) · United Kingdom (2) · Bulgaria (1)
MoonSun Choi (2) · Yinghong Wang (2) · Adriana Tremoulet, MD, MAS (1) · Amit Assa, MD (1) · Byong Duk Ye, MD, PhD (1) · Dag Arne L Hoff, md, phd (1) · Dr Hira Tariq, MBBS, FCPS Derma (1) · Dr. Faria Asad (1) · Dr. G D'Haens, Phd MD (1) · Dr. Nabigha Khalid (1) · Dr. Saleha Batool (1) · Dr. Sumera Hanif (1) · Dr. Talat Masood Akbar (1) · Geert DHaens (1)
PMID 33676969, PMID 14632813, PMID 17587838, PMID 28502609, PMID 29411318, PMID 30229280, PMID 30762274, PMID 30929895, PMID 32965617, PMID 33230526, PMID 33245751, PMID 34216825, PMID 34377890, PMID 34732500, PMID 35435862, PMID 35673354, PMID 36534825, PMID 36694613, PMID 37004656, PMID 37038897, PMID 38365502, PMID 39390697, PMID 42557857, PMID 42617793
2016 (3), 2014 (1)